Filtered library · Archetype
Earnings inflection · 82 dossiers
Dossiers classified as Earnings inflection — 82 names, each with its thesis, invalidation trigger and catalyst calendar.
All dossiersSYRE
Spyre Therapeutics, Inc.
Accelerating TL1A/I&I platform: SPY001 Part A de-risked UC (Robarts −9.2, p<0.0001); next leg is SPY002 "mid-2026" open-label Part A induction. Abivax obefazimod's Phase 3 malignancy signal (6/4) cleared an oral UC competitor and drove DB…
SMR
freshNuScale Power Corporation
Undated South Korea $200B-package binary (NuScale Tennessee/Uljin SMR; Doosan + Samsung C&T) is the only live leg, but the June 1–2 pop to ~$14 fully round-tripped and broke to a $10.50 close (6/5) on 45%-above-avg volume, pressing the…
DRTS
Alpha Tau Medical Ltd.
Commercial-validation leg accelerating: Tolmar's 2026-06-03 US prostate deal ($35M upfront, up to $161.5M milestones, $20M equity at a 34% premium) stacked on strong 2026-06-01 ASCO pancreatic OS data (median up to 17.1mo) and two analyst…
LQDA
Liquidia Corporation
YUTREPIA ramp accelerating (Q1'26 net sales $129.9M, +44% QoQ, profitable) and the legal tail just got cut: the 2026-06-04 SCOTUS Hikma v. Amarin skinny-label ruling takes forced NDA withdrawal off the table, shifting the '327 trial…
CORT
Corcept Therapeutics Incorporated
Post-CRL redemption arc largely complete: stock round-tripped $28.66→$91 high, now $72.62. Live leg is Cushing's second-approval optionality NDA resubmission announced 2026-05-27 (no new trials, PDUFA ~late 2026). Q1 missed (+4.9% YoY, net…
DNTH
Dianthus Therapeutics, Inc.
The narrative already paid out: gMG Phase 2 read positive (Sep-2025), CIDP CAPTIVATE hit an early Phase 3 GO (Mar-2026), sell-side fully caught up ($121 consensus PT, $16→$96 52-wk run) and a $719M raise at $81 closed Mar-12. Now…
ELVN
Enliven Therapeutics, Inc.
De-risking BCR::ABL1 story: ELVN-001 Phase 1 ENABLE update hits an EHA oral June 11 (T-4) plus webcast 69% cumulative MMR (60/120mg) and 52% in asciminib-pretreated CML, no MTD, $462.6M cash into 1H-2029, Phase 3 ENABLE-2 launching…
MGTX
MeiraGTx Holdings plc
Gene-therapy shots-on-goal re-rate has cooled from ACCELERATING to MATURING after the Apr cluster (J&J bota-vec buyback, xerostomia Breakthrough, Hologen up-to-$430M). Stock rolled ~24% off the $11.85 high and on 2026-06-05 closed $9.00,…
RLAY
Relay Therapeutics, Inc.
Binary resolved bullish: zovegalisib (RLY-2608) posted ~11-mo PFS, won FDA Breakthrough Therapy, and is funded into 2029 sell-side re-rated to $26–$28 (from $18–$21) as shares broke to a 52-wk high $17.33. The leg now is the post-data…
TNGX
Tango Therapeutics, Inc.
Binary PRMT5 catalyst resolved upside: vopimetostat's Oct-2025 Ph1/2 data (27% ORR across 16 tumor types; 2L MTAP-deleted PDAC 25% ORR/7.2mo PFS; FDA-aligned 250mg) de-risked the asset and drove a $3→$28 re-rate. Now ~$20, digesting below…
TSHA
Taysha Gene Therapies, Inc.
Rett gene therapy narrative re-rated from clinical binary to BLA execution: FDA aligned on a single-arm pivotal with potential BLA off the REVEAL six-month interim, cash funded into 2028 kills the dilution overhang, and Part A shows 100%…
TVTX
Travere Therapeutics, Inc.
FILSPARI FSGS launch confirming, not round-tripping: June brought a second target wave (Citi $62, HC Wainwright $67, Wedbush $55), a USPTO patent allowance + Orange Book listing extending exclusivity, and the 2026-06-02 Everest…
ZVRA
freshZevra Therapeutics, Inc.
MIPLYFFA's generic-cliff risk was just removed to 2041 (Orange Book patent + PTE filing, 2026-06-08), triggering a six-firm PT-raise cluster ($25–35) while the drug's ramp runs +78% YoY. A re-rating of a debt-free, cash-generative…
AAPL
freshApple Inc.
WWDC ~6/8 binary today; MATURING ai-mag7 theme, $4T mega-cap (±5-10% asymmetry) dilutes alpha on the book, edge +3.3pp fails rule 2. Consistent with prior deferrals wait for the print.
ABCL
AbCellera Biologics Inc.
Busted-platform turnaround re-rated ~190% off the $2.33 low on ABCL635 Phase 1 success + Q1 beat (+98% YoY) + PT hikes (Cantor $11). The Q3 2026 ABCL635 Phase 2 VMS topline is the binary but it's a quarter out, and the tape just spiked to…
ACB
Aurora Cannabis Inc.
Sentiment-beta proxy on the U.S. reschedule trade, but the wrong horse: a Canadian LP with no U.S. THC ops, lagging at its 52-wk low ($3.46) while MSOS rips +7.6% (Jun 4) into the Jun 29 DEA hearing. Jun 11 pre-open earnings is the nearer…
ACDC
ProFrac Holding Corp.
Hormuz oil-shock beta is now UNWINDING, not accelerating: ACDC −10.1% on 2026-06-05 as the US President called Iran talks "progressing well," Iran signaled a Strait reopening, and Brent broke <$90 (WTI $91.40). The de-escalation headline…
ANAB
AnaptysBio, Inc.
April 2026 spin-off turned ANAB into a pure-play royalty company (Jemperli/GSK + imsidolimab/Vanda) after shedding its entire clinical pipeline and $100M cash to First Tracks (TRAX). Value now hinges on one binary: the July 14–17 Delaware…
APGE
Apogee Therapeutics, Inc.
Defining binary resolved 2026-05-27: APG777/zumilokibart Part B hit (mid-dose 65.9% EASI-75, all doses p<0.001) and a record $1.3B Blackstone non-dilutive deal landed yet shares sold the news (~$95→$83) on a non-monotonic dose curve (mid >…
ATAI
AtaiBeckley Inc.
Consolidated-psychedelic-leader narrative already fired AtaiBeckley merger, 22.4% Compass stake, both COMP360 Phase 3 wins, BPL-003 EOP2 cleared. On 2026-06-05 the tape lost the $4.00 shelf (−12% to $3.95) in a risk-off session, opening an…
ATEX
freshAnterix Inc.
Spectrum re-rating already paid: FCC's 2026-02-18 final rule lifting 900 MHz broadband to 10 MHz (implied $2.5–7B+ value) drove a ~3.7x run to the 52-wk high $67.19. Theme now MATURING B. Riley cut to Neutral 2026-06-04 (PT $69 ≈ spot),…
AVNS
Avanos Medical, Inc.
All-cash $25.00/share take-private by American Industrial Partners (announced 2026-04-14, EV $1.272B, no financing condition) converted AVNS into a merger-arb pin. Narrative is dead; tape sits a few percent under the cash floor until a…
BAK
Braskem S.A.
Multi-year Novonor controlling-stake sale CLOSED June 2026 (Shine I FIP/IG4 + Petrobras co-control); the defining binary resolved as a sell-the-news ADR hit fresh lows ($3.48, -7.45% on 2026-06-05). JPM went Overweight (PT $5.50) on a…
BBNX
Beta Bionics, Inc.
Broken growth (new patient starts -10-20% seq) bouncing into ADA on RSI 82.3 parabolic off a busted base; litigation circling event-relief, not a trend.
BTGO
BitGo Holdings, Inc.
Broken-IPO falling knife: down ~69% from its $18 Jan-2026 IPO to ~$5.56, printing fresh all-time lows after slicing the prior $5.42 floor. Real crypto-custody franchise landing weekly enterprise deals, but EBITDA-negative, dead tape, and a…
CADL
Candel Therapeutics, Inc.
Phase 3 prostate-cancer win is now fully public Lancet Oncology print (2026-06-02), AUA extended follow-up (HR 0.70, 39% PCa-specific DFS gain) and the tape barely moved. The April accelerating leg (Cantor OW, EVERSANA, $4→$9) has matured…
CCRN
Cross Country Healthcare, Inc.
Pinned cash merger-arb, not a momentum trade. Knox Lane (PE, no staffing overlap) is taking CCRN private at $13.25 cash; stock $13.18 (Jun 5 close) = ~0.5% gross spread. HSR waiting period lapses 2026-06-22 absent a second request. Upside…
CGC
Canopy Growth Corporation
Cannabis Schedule III narrative is ACCELERATING federally (DEA adult-use rescheduling hearing 2026-06-29→07-15), but CGC is a diluted Canadian proxy at $1.04 near its 52-wk low, with a restatement-bundled 2026-06-15 print arriving first.…
CMPS
COMPASS Pathways Plc
Late-April FDA catalyst (NDA rolling review + National Priority Voucher for COMP360 in TRD) has faded into dead tape; theme stepped ACCELERATING→MATURING and volume is back to ~1x ADV. No dated catalyst in 30d the real binary is the…
CNTA
Centessa Pharmaceuticals plc
Closed deal, not a trade: Eli Lilly's definitive ~$6.3B-cash + up to $1.5B-CVR acquisition (announced 2026-03-31, ~40% premium) capped the orexin story at the bid. Stock pinned near the ~$40 cash value, PTs clustered $40–42, post-M&A…
CODI
Compass Diversified
Post-fraud recovery has already played out: 10-K/A restatement filed 2025-12-08, Lugano fraud ruled isolated, Sterno sold (~$280M), common tripled off a $4.58 low to a $12.64 high (+128% YTD). At ~$10.64 it trades above every analyst PT…
CPIX
Cumberland Pharmaceuticals Inc.
3x re-rate off $1.85 to $5.77 is the $100M Apotex asset-sale (announced 2026-04-22; $75M cash upfront + $25M earnout) vs $87M cap public and priced. The 2026-06-24 shareholder vote is the only dated binary, but the board recommends FOR, so…
CRVS
Corvus Pharmaceuticals, Inc.
Single-asset ITK-inhibitor binary RESOLVED: soquelitinib's 2026-05-14 Phase 1 atopic-dermatitis data printed clean (up to 75% EASI-75, durable off-drug remission), yet shares SOLD the news ~-28% and now sit ~$11.12 vs a $26.95 52-wk high.…
DSGN
Design Therapeutics, Inc.
Only 2026 binary already fired against momentum: RESTORE-FA topline (2026-05-18) gapped +14% then closed -28.88% at $10.22 as n=16 open-label 4-week data underwhelmed the run toward $17. Now drifting low-$10s ($10.65, 2026-06-05) with no…
ERAS
Erasca, Inc.
Pan-RAS molecular-glue binary that already split: ERAS-0015 posted best-in-class early Phase 1 ORRs (62–75% NSCLC) on 2026-04-27, then shares fell ~48% on a treatment-related Grade 5 pneumonitis death plus Revolution Medicines' '225-patent…
ESPR
Esperion Therapeutics, Inc.
Take-private kills the momentum trade: ARCHIMED $3.16/sh cash + CVR (announced 2026-05-01, close Q3-2026) pins the stock at the deal price. Last ~$3.14 = ~0.6% arb spread to cash plus a near-free CVR fixed-income-shaped, not narrative…
FWRD
Forward Air Corporation
Strategic review ended with NO buyer (confirmed 2026-05-08) Clearlake/Apollo walked and a ~$250M customer (~10% of revenue) is leaving starting 2027. The deal-premium thesis that was the only reason to watch this is dead; PTs slashed to…
GBTG
Global Business Travel Group, Inc.
Signed take-private: Long Lake buys Amex GBT at $9.50/share cash (~$6.3B), close 2H 2026, 69% of holders locked via voting agreements. Stock pinned under $9.50 pure merger-arb, ~1.7% capped upside vs ~36% deal-break tail. No momentum leg;…
GCO
freshGenesco Inc.
Q1 FY27 binary fired beat-and-raise (Journeys +5%, 7th straight positive-comp quarter, FY adj-EPS guide lifted to $2.00–2.40). Live activist proxy contest (Radoff/Jumana ~8%, 4 board nominees) is the next catalyst. But the earnings event…
IHRT
iHeartMedia, Inc.
M&A special-sit the only live leg decayed from "on ice" (NYT, 2026-05-29) to "fizzled out" (thedesk.net, 2026-06-01) over the same station-divestiture/antitrust impasse; the $6.56 deal-spec spike has fully round-tripped to ~$4.40. No…
INBX
Inhibrx Biosciences, Inc.
Post-spike DR5-agonist biotech bleeding in a catalyst vacuum: $155→$87 (-44%), sold its own HNSCC beat, now grinding toward the $78 floor. Chondrosarcoma BLA confirmed submitted; FDA filing-acceptance decision (~late June, soft) is the…
IRWD
Ironwood Pharmaceuticals, Inc.
Thesis inverted vs prior coverage: Linzess wasn't a melting ice cube a 2026 AbbVie pricing restructure (lower list, lower gross-to-net) drove US net sales +97% YoY (Q1 $272.5M), FY EBITDA guide >$300M. Apraglutide binary is dead for years…
JBIO
Jade Biosciences, Inc.
Binary fired 2026-06-01 JADE101 Phase 1 beat (~70% IgA, q12w dosing, clean safety), PTs jumped (BTIG $74) but the tape sold the news and the company printed a dilutive $150M raise at $15.00 (2026-06-04). Catalyst spent; next own readout is…
JOBY
Joby Aviation, Inc.
eVTOL cert narrative still accelerating (FAA Stage 4/5, Dubai 2026 first-passenger target), but price broke down ~12.4% on June 5 to ~$9.76 on no news, losing the 200-day and testing the 50-day EMA. Recovery base failing into…
KALV
KalVista Pharmaceuticals, Inc.
Near-closed $27.00/share all-cash Chiesi takeout: all antitrust/FDI gates cleared (HSR 5/28, Germany 5/27, Italy 5/29); only the majority-tender condition remains, expiring 2026-06-10. Stock pinned ~$26.66, ~1.3% to deal vs ~40% break…
LOVE
The Lovesac Company
Q1 FY27 prints BMO 2026-06-11 (call 8:30 ET) a hard binary into a company-guided LOSS quarter (rev $133–139M, EPS −$1.22/−$0.95) with shares near 52-wk lows (~$15.7 vs $10.33–$21.15 range). The 2026-03-26 beat pop (+23.7%) fully faded;…
MGM
freshMGM RESORTS INTERNATIONAL
Take-private special situation: Barry Diller's People Inc. Bid $48.30/share cash (~$18B) on 2026-06-01; stock gapped to within a few percent of the bid. The narrative leg already fired what's left is capped merger-arb spread (~3-5% up vs…
NKTR
Nektar Therapeutics
Feb-2026 REZOLVE-AD (atopic dermatitis) maintenance pop to $109 has fully round-tripped: NKTR is ~$57, ~38% below the $92 April secondary, -32.6% on the month with no near-term binary. The AD IL-2 Treg narrative ran ACCELERATING then…
NVCR
NovoCure Limited
TTFields single-asset name marked up into a binary: +24.5% over 3mo to ~$16, recovering toward the $19.25 high ahead of the Phase 3 TRIDENT GBM overall-survival readout (topline Q2 2026, ~June 30). coin-flip the edge is buying a confirmed…
OGN
Organon & Co.
Takeover binary already resolved: Sun Pharma signed a definitive $14.00/share all-cash merger (2026-04-26, $11.75B EV, 103% premium) and no Grünenthal topping bid emerged. OGN now trades as deal-pinned merger-arb ~6% spread to an…
OLPX
Olaplex Holdings, Inc.
Turnaround binary is moot: OLPX agreed 2026-03-26 to an all-cash Henkel takeout at $2.06/share (~$1.4B). Stock pegged ~$2.04 (~1% to deal, capped). Advent already approved by written consent 2026-05-04; only antitrust clearances remain. No…
OMER
Omeros Corporation
Both binary catalysts already fired Novo Nordisk zaltenibart deal (closed 2025-12-01, $240M cash) and FDA approval of YARTEMLEA for TA-TMA (2025-12-23). Now a one-quarter-old launch ramp (Q1 net sales $9.9M) at ~$10.74, -39% off the $17.65…
ORKA
Oruka Therapeutics, Inc.
Phase 2a binary already fired positive (2026-04-27: 63.5% PASI 100, 83% PASI 90 — bimekizumab-class clearance from a twice-yearly IL-23). The accelerating leg is now spent: stock topped $91, sits ~$60 and bleeding into a June 2026 lock-up…
OSCR
Oscar Health, Inc.
ACA pure-play doubled off its low, now above every analyst PT after Wells Fargo capitulation, on a stalled binary subsidy deal late recovery chase near 52w highs.
PAYO
freshPayoneer Global Inc.
Pure M&A special situation: Nuvei is reportedly in advanced talks (Reuters, June 9) to buy Payoneer for ~$2.7B equity value (~$8/sh implied), and the tape already gapped +24% on the leak. At ~$6.75 the remaining merger-arb spread pays only…
PAYS
Paysign, Inc.
Q1 (2026-05-12) resolved the binary bullish revenue +50.8% YoY, EPS $0.09 beat $0.07, Patient Affordability +168%, Part-D-cap fear disproven, FY26 guide $106.5–110.5M. But the beat got sold (+3% reaction) and price sits ~23% below the…
PENG
Penguin Solutions, Inc.
Agentic-AI demand drove an FY26 guide raise (~6%→12% net-sales growth), reaffirmed June 1 at the high end, plus Rosenblatt/Stifel PT raises to $65–66 a real narrative inflection that ran shares from $16 to an ATH $73.24 (June 2). Now a…
PLAY
freshDave & Buster's Entertainment, Inc.
Beaten-down arcade-restaurant turnaround: "back-to-basics" has comps climbing from ~-9% toward flat, the Street models the first positive revenue quarter (+1.7% YoY) on the 2026-06-15 AMC print, and a short book at >8 days-to-cover is…
PLSE
Pulse Biosciences, Inc
Biotech ACCEL (first coverage Canaccord $32 + insider ATM buying) but the de-risking data is 2027, no 30-day binary, ~$18M/qtr burn momentum probe, not a fat pitch.
PSNL
Personalis, Inc.
MRD/liquid-biopsy narrative still ACCELERATING on 4 Medicare wins + best-in-class ASCO data, but the catalysts already fired and price just FAILED a breakout 2026-06-05 printed a fresh 52w high $12.53, then reversed to close $10.75 (-11%).…
QURE
uniQure N.V.
FDA-regime-change relief rally into binary catalysts: Makary's 2026-05-12 ouster plus the acting commissioner's 2026-06-04 pledge against political interference in rare-disease reviews revived hope of an accelerated path for AMT-130…
RAMP
LiveRamp Holdings, Inc.
Pending all-cash takeout, not a momentum name: Publicis $38.50/share cash deal (signed 2026-05-16) pins RAMP at $37.42 (June 5), a ~2.9% arb spread to a year-end-2026 close. Upside capped at the contract price; deal-break downside ~-21%…
RAPP
Rapport Therapeutics, Inc.
AAN follow-up (2026-04-21) confirmed RAP-219 durability 90% median seizure reduction wks 9-12, 22-day half-life validating the platform, but the stock sold the news ~9% and now sits in a ~5-month data gap until bipolar-mania Phase 2…
RIVN
freshRivian Automotive, Inc.
Structurally broken active death cross + open NHTSA safety probe + no theme membership, -31% YTD; R2 launch a hope-trade into a rolled-over chart.
RLMD
Relmada Therapeutics, Inc.
Post-Phase-3-failure CNS microcap in a dead readout zone; the 2026-05-28 vote lifting authorized shares 150M→200M arms an ATM with no dated Sepranolone or RELIGHT topline to offset it. The 2026-06-03 pre-market pop was a low-float blip on…
RLYB
Rallybio Corporation
Reverse-merger special situation, not a momentum trade. The 2026-06-01 Avenzo oncology merger + $215M PIPE pop already fired and has faded back toward the mid-$14s by 2026-06-07. Legacy holders keep a cash distribution + CVR + a ~2.8%…
RMAX
Re/Max Holdings, Inc.
Merger-arb shell, not a momentum name. REAX's near-all-stock takeover (5.152 REAX/share, $60-80M cash cap) is worth ~$8.7 in stock at REAX $1.68; RMAX trades ~$9.05, near parity. Thin spread, ~35% downside on a break, no narrative leg…
RPAY
Repay Holdings Corporation
Two-activist takeout arb resolved against longs: the board rejected Forager's $4.80 bid (5/4, "significantly undervalues") and closed the $372M debt-funded KUBRA deal (6/1), the defensive move Veradace feared. Stock round-tripped to…
RZLT
Rezolute, Inc.
Biotech ACCELERATING leader: upLIFT 6/8 interim + 4-house upgrade cluster, 5 rules incl vol 1.53x binary name, LOW event-risk probe.
SLS
SELLAS Life Sciences Group, Inc.
Pre-binary retail run-up: SLS ran ~5x off the $1.39 low into an imminent, event-driven Phase 3 REGAL overall-survival readout (78/80 death events as of May 11, 2026). A coin-flip near 52-week highs ($8.23) with parabolic RSI lottery gamma…
SMMT
Summit Therapeutics Inc.
Single-asset ivonescimab story where the leg that powered the ASCO run has resolved mixed: the global HARMONi-3 squamous PFS interim missed (Apr 30, −25%), then positive China-only HARMONi-6 OS (HR 0.66) sold the news (Jun 1, −6%).…
STAA
STAAR Surgical Company
Post-Alcon-break special situation, not a momentum leg: shareholders killed the $30.75 takeout (Jan 6 2026), Broadwood (~31%) holds three board seats pushing a standalone ~$50 path. China EVO+ recovery is real (Q1 +119.6% YoY, EPS $0.29 vs…
STRO
Sutro Biopharma, Inc.
Equity re-minted around STRO-004, a DAR-8 Tissue Factor ADC, after lead luvelta was shelved. Analyst cluster (Wedbush $60, Barclays OW $56) frames a mid-2026 Phase 1 readout, but the stock has rolled over from ~$41 to ~$26 momentum fading…
TBRG
TruBridge, Inc.
Closed all-cash merger in its closing window, not a momentum setup: IKS Health buying TruBridge at $26.25 cash, definitive proxy filed, shareholder vote 2026-07-07. Stock pinned ~$26 = ~1% gross spread to a Q3 2026 close. The narrative leg…
TLRY
Tilray Brands, Inc.
Cannabis Schedule-III reform trade live into the 2026-06-29 DEA adult-use rescheduling hearing (concludes ≤07-15); sector firming (CGC adult-use +43%) and a Congressional hemp-THC ban would clear gray-market competitors but TLRY's chart is…
TRVI
Trevi Therapeutics, Inc.
De-risking binary already fired: positive CORAL Phase 2b (IPF cough, 60.2% reduction, p<0.0001, June 2025) plus JAMA publication. Funded into 2030 after the April raise, but the next clinical topline is H2 2027 a ~14-month catalyst desert.…
ULCC
Frontier Group Holdings, Inc.
The SAVE-grounding binary already fired Spirit exited and Frontier's 2026-05-05 call guided ~20% Y/Y Q2 RASM growth on absorbed capacity. The trade is now a fuel-cyclical: ULCC re-rates only if jet fuel rolls over enough to push that RASM…
USO
freshUnited States Oil Fund, LP
Iran's risk premium and the physical Hormuz cut (5–6M bbl/day) that lifted WTI are unwinding together: a US–Iran MoU is reportedly signable this weekend/Monday and explicitly reopens Hormuz, returns Iranian barrels and unlocks frozen…
VECO
freshVeeco Instruments Inc.
VECO is now a merger-arb proxy for Axcelis, not a standalone semicap: all-stock deal at 0.3575 ACLS/share, both shareholder votes approved (~Feb 2026), pending only China SAMR, close targeted 2H 2026. The 2026-06-09 NSA500 follow-on order…
VIR
Vir Biotechnology, Inc.
The binary already resolved up: Feb 23 Astellas collaboration (up to $1.7B; $315M upfront) plus clean Phase 1 VIR-5500 data (no DLTs, 82% PSA50, 45% ORR) de-risked the PRO-XTEN masking story and the cash runway (now into H2 2028). Stock…
WGS
freshGeneDx Holdings Corp.
Busted-growth genomics name: the May 4 print cut FY26 guide 12% and broke reimbursement (ARR ~$3,300, ~$200 light). Price has doubled off the $32 low to ~$60, but that's a recovery bounce ahead of the binary early-August Q2 ARR print, not…
XTLB
freshXTL Biopharmaceuticals Ltd.
Binary Nasdaq delisting rescue, not a momentum setup. XTLB ($5.5M cap, $2.13, fresh 52-wk low $2.01) is a public shell that must close the Psyga Bio psychedelics reverse-merger + $1.5M raise and regain full listing compliance by 2026-06-30…